NCT05603832 - A Phase 3 Study of F14 for Management of Pain Following Total Knee Replacement | Biotech Hunter

Enrollment

151

Participants

Timeline

Start Date

November 17, 2022

Primary Completion Date

November 22, 2023

Study Completion Date

August 31, 2024

Conditions

Post Operative Pain

Interventions

DRUG

F14

625 mg intra-articular sustained-release celecoxib

DRUG

0.25 % Bupivacaine HCl

Local anesthetic

DRUG

Acetaminophen

Analgesic

DRUG

Methocarbamol

Muscle relaxant

Trial Locations (7)

Phoenix Clinical Research, Tamarac

Woodland International Research Group, Little Rock

The Orthopedic Center, Tulsa

HD Research - Legent Orthopedic Hospital, Carrollton

HD Research - First Surgical Hospital, Bellaire

Endeavor Clinical Trials, San Antonio

CenExel JBR, Salt Lake City